[Edaily Reporter KIM JI-WAN ] SCL Science(246960) Subsidiary Neogen Logic is pursuing a treatment strategy that combines an ovarian cancer drug with a patient-tailored cancer vaccine to delay recurrence.
This approach involves suppressing cancer cells with existing treatments while using the vaccine to induce the patient’s immune cells to attack the cancer. The plan is to tackle the risk of recurrence that persists even after anticancer treatment through a combination of medication and an immune response.
Choi Jeong-kyun, CEO of NeoGenLogic and a professor at the Korea Advanced Institute of Science and Technology (KAIST), explains the company’s personalized cancer vaccine pipeline during a research and development (R&D) briefing held on September 29 at the KYOBOSECURITIESCO.,LTD. headquarters on Uisadang-daero in Yeongdeungpo-gu, Seoul. (Photo:KIM JI-WAN Reporter)
According to NeoGenLogic on the 11th, the company is developing “DLV-T1,” a personalized messenger ribonucleic acid (mRNA) cancer vaccine targeting ovarian cancer. The primary goal is “maintenance therapy” to sustain the effects of anticancer treatment for an extended period and delay recurrence. The company plans to submit an Investigational New Drug (IND) application in the second half of next year and administer the vaccine to the first patient in a Phase 1 clinical trial in 2028.
Adding
a Vaccine to Existing Drugs… A ‘Dual Attack’ to Delay Recurrence
The development strategy for DLV-T1 is to combine existing therapies with an immune cell attack. PARP inhibitors are targeted anticancer drugs that prevent cancer cells from repairing damaged DNA. By using a vaccine to inform the immune system of the cancer cells’ characteristics, the drug’s mechanism of action and the immune response can be leveraged together.
Choi Jeong-kyun, CEO of Neogen Logic and a professor at the Korea Advanced Institute of Science and Technology (KAIST), said, “We have discussed with clinicians the plan to evaluate vaccine monotherapy in Phase 1 clinical trials for ovarian cancer maintenance therapy, and to assess, in a Phase 1b trial, how effective the vaccine is when added to PARP inhibitor monotherapy.”
First, the vaccine will be administered alone to confirm safety and immune response. The plan is then to compare a group of patients receiving only the PARP inhibitor with a group receiving the vaccine in combination, to evaluate the therapeutic benefit gained by adding the vaccine.
The research is being conducted in collaboration with researchers at Severance Hospital. Patient tissue is being provided by researchers with global clinical experience in ovarian cancer and PARP inhibitors, and the team is examining the immune responses when the drug and vaccine are administered separately or in combination.
CEO Choi explained, “We are examining the extent of the immune response when the drug is administered alone or in combination, using ovarian cancer tissue provided by patients,” adding, “Although these are currently in vitro experiments, we are observing strong immune responses in the patient tissue.”
Next, the company plans to explore combining the treatment with immune checkpoint inhibitors for patients whose cancer has recurred after PARP inhibitor therapy. This combination works by having the immune checkpoint inhibitor release the “brakes” that suppress immune cell activity, while the vaccine identifies the cancer targets to be attacked. The company’s strategy is to expand its development scope from maintenance therapy to treatment following recurrence.
Each Patient’s Immune System Is Different… AI Selects ‘Targets to Attack’
DLV-T1 targets proteins and other molecules produced in high quantities by cancer cells. These are known as “tumor-associated antigens.” While they are found in high concentrations in cancer, they are also present in normal cells.
As a result, the immune system may recognize these proteins as familiar components of the body and fail to mount a sufficient attack. This is known as “immune tolerance.” NeogenLogic addresses this issue through a personalized design that identifies regions most likely to elicit an immune response in each individual patient.
CEO Choi stated, “Since tumor-associated antigens are also present in normal cells, there is the problem of immune tolerance,” adding, “We have developed a strategy to circumvent this tolerance by creating personalized vaccines rather than universal ones.”
The key tools are the company’s proprietary AI platforms, DeepNeo and LexiNeo. Since each patient’s immune system is different, these platforms predict which specific regions of a given cancer protein will elicit the strongest immune response. This technology bridges the gap between identifying cancer characteristics and selecting targets to which the patient’s body will actually respond.
DLV-T1 development timeline. (Courtesy of Neogen Logic)
CEO Choi explained, “DeepNeo is a core platform capable of comprehensively integrating and predicting everything from how cancer antigens bind to a patient’s MHC to inducing T-cell and B-cell responses.”
The MHC acts as a “display platform” that presents protein fragments on the cell surface to immune cells. T cells recognize the fragments presented there and either attack cancer cells or assist other immune cells. B cells also participate in the immune response by producing antibodies and presenting antigens. The company designs vaccines by examining everything from whether the target is presented effectively to whether immune cells will respond.
The selected targets are encoded into mRNA. The mRNA acts as a blueprint that instructs the body to produce the corresponding targets. This approach induces the immune system—which has first encountered the cancer’s characteristics through the vaccine—to recognize and attack cancer cells with the same characteristics.
The company is also preparing a production system for vaccines to be used in clinical trials. Neogen Logic is responsible for target selection and mRNA design, while production and delivery technology will be secured through collaboration with external specialized companies. The delivery vehicle, lipid nanoparticles (LNPs), are small lipid particles that protect the mRNA and transport it into cells.
CEO Choi stated, “We are pursuing contracts with mRNA production companies and firms that possess LNP technology.” He added, “In Japan, we have signed a contract with EPS, a contract research organization (CRO), and are establishing a local clinical and manufacturing partnership.”
A $5.6 Billion Market… Targeting “Combination Vaccines” That Enhance the Efficacy of Existing Drugs
Ovarian cancer treatment primarily consists of surgery and chemotherapy. Depending on the patient’s genetic characteristics and treatment response, PARP inhibitors or drugs that block the formation of blood vessels that supply nutrients to tumors are used for maintenance therapy.
However, issues remain, such as recurrence after treatment or the development of resistance to existing drugs. The U.S. National Cancer Institute (NCI), in its guidance on the treatment of recurrent ovarian cancer, identifies the response to prior treatment and the timing of recurrence as key criteria for treatment selection.
Global pharmaceutical companies are also targeting this treatment need. AbbVie’s “Elahier” is an antibody-drug conjugate (ADC) in which an anticancer agent is attached to an antibody that targets cancer cells. In 2024, the U.S. Food and Drug Administration (FDA) officially approved it as a treatment for certain cancers, such as ovarian cancer, that are positive for the folate receptor alpha (FRα) and resistant to platinum-based chemotherapy.
Development efforts to enhance treatment efficacy by combining existing drugs are also underway. In its Phase 3 “DUO-O” clinical trial, AstraZeneca evaluated a strategy that combines chemotherapy, immunotherapy, and anti-angiogenic agents, followed by maintenance therapy that includes a PARP inhibitor. Competition in ovarian cancer treatment appears to be advancing simultaneously through both the development of new drugs and the expansion of combination therapies.
According to Grand View Research, the global ovarian cancer treatment market is projected to reach $5.65 billion (7.5461 trillion won) by 2030. The compound annual growth rate is expected to be 6.6%.
CEO Choi emphasized, “DLV-T1 is positioned as a ‘patient-tailored combination vaccine’ that complements existing treatments,” adding, “Our strategy is to use PARP inhibitors to make it difficult for cancer cells to survive, while the vaccine engages the patient’s immune system to join the attack.” He continued, “Neogen Logic will pave the way for sustaining treatment efficacy for a longer period by combining individualized immune responses with drug-based maintenance therapy for ovarian cancer.”
“The bond market should be a universal channel for corporate financing, but right now it’s like an exclusive social club.”This was the point raised by an advisory committee member during a meeting hel…
KYOCHON FOOD&BEVERAGE, operator of the Kyochon Chicken franchise, is expanding its sales channels for traditional Korean liquor by introducing its premium makgeolli, “Eunhwasu: A Night of Stargazing 1…
SillaJen, Inc.(215600)The company is receiving government support for the development of “SJ-650,” a next-generation anticancer viral therapy administered via intravenous injection. It plans to accele…